

Cumulative Index

Volume 35, Numbers 1-4, 1992

Abortion, ethical issues in. *See Ethics, obstetric*
Abruptio placentae, ultrasonography of, 527
Adhesiolysis, hysteroscopic, 235
 lasers in, 247
 in office setting, 276
 resectoscope in, 254
AIDS in pregnancy, ethical issues in, 813
Albumin
 infusions of, and fluid management during labor, 514
 urinary, in preeclampsia prediction, 360
Alcohol intake
 in pregnancy, and ethical challenges in medical care, 803
 and premenstrual syndrome, 676
Alexandria unit of uterine contractility, 546
Alpha-fetoprotein, in preeclampsia prediction, 358
Alprazolam, in premenstrual syndrome, 634, 664
Amino acid levels, in intrauterine growth retardation, 126
 γ -Aminobutyric acid receptors in brain, progesterone metabolites affecting, 612
Amniotic fluid volume, and intrauterine growth retardation in oligohydramnios, 126, 172, 185
Amniotomy, affecting labor and fetal status, 535
cAMP, affecting uterine contractility, 494
Ampullosalpingoscopy, 300
Analgesia in labor
 after prior cesarean section, 445
 agents affecting uterine activity in, 457
Androgens, as therapy for menopausal symptoms, 884
Anencephaly
 and concepts of brain life and brain death, 720
 and infants as organ donors, 821
 management in third trimester, 792
Anesthesia management, in preeclampsia, 414
Aneuploidy, fetal growth patterns in, 119
Angiotensin sensitivity test, in preeclampsia prediction, 355
Anticonvulsants, in eclamptic seizures, 366
Antidepressants, in premenstrual syndrome, 634, 664
Antithrombin III, 339
 serum levels
 in preeclampsia, 343
 in pregnancy, 340
 as therapy in preeclampsia, 347

Asphyxia at birth, antenatal existence of, 126
Aspirin, in preeclampsia prevention, 352
Atenolol, in premenstrual syndrome, 664
Atherosclerosis, postmenopausal estrogen therapy affecting, 894

Balloon catheters, for cervical ripening, 476
Barbiturates, affecting uterine activity in labor, 457
Behavior patterns, fetal, assessment of, 185
Behavioral therapy, in premenstrual syndrome, 690
Bellergal-S, as therapy for menopausal symptoms, 884
Benzodiazepines, affecting uterine activity in labor, 457
Bethesda system for cervical/vaginal cytologic diagnoses, 22
Biophysical profile, fetal, 185
Biopsies, fine-needle aspiration, in gynecologic tumors, 73
Bisphosphonates, in osteoporosis, 901, 913
Bleeding, vaginal, and endometrial sampling guidelines, 28
Blood flow studies in pregnancy
 Doppler velocimetry, 155, 357, 387
 in hypertension, 387
 in intrauterine growth retardation, 126, 155
 in preeclampsia, 375
 uteroplacental, 108
Blood gases, in fetal hypoxia, 126, 185
Blood pressure
 in early pregnancy, and risk for preeclampsia, 354
 portable monitoring devices in pregnancy, 395
 studies in preeclampsia, 375
Bone
 densitometry of, 901, 913
 life cycle of, 901
Brain life and brain death, concepts of, 720, 821
Braxton-Hicks contractions, 546
Breast cancer, risk in estrogen therapy, 871, 923
Breath presentation
 ultrasound guidance in, 527
 vaginal delivery in, 559
Bromocriptine, in premenstrual syndrome, 634, 664
Bupivacaine, affecting uterine activity in labor, 457
Busrelin, in premenstrual syndrome, 655
Buspirone, in premenstrual syndrome, 634, 664

CA125 antigen, as marker in gynecologic cancers, 45
Caffeine intake, and premenstrual syndrome, 634, 676
Calcitonin
 gene-related peptide levels in preeclampsia, 328
 therapy in osteoporosis, 901, 913

Page numbers listed are those on which relevant article begins.

Calcitrol therapy, in osteoporosis, 901
 Calcium
 affecting uterine contractility, 494
 intake of
 and osteoporosis prevention, 901, 913
 and premenstrual syndrome, 634, 676
 platelet, in preeclampsia, 360
 urinary, in preeclampsia prediction, 360
 Cameras, video, in operative hysteroscopy, 218
 Cancer, gynecologic. *See* Tumors
 Carbohydrate intake, and premenstrual syndrome, 634, 676
 Carbon dioxide for distention of uterus in hysteroscopy, 216, 227, 272, 273, 283
 complications from, 258
 Cardiac output in preeclampsia, 375
 Cardiopulmonary arrest, in preeclampsia, 410
 Cardiovascular disease, postmenopausal estrogen therapy affecting, 894
 Cerebral edema, in preeclampsia, 514
 Cervix uteri
 cancer of
 and Bethesda system for cervical/vaginal cytologic diagnoses, 22
 integration of CT and MRI for treatment planning in, 55
 and molecular biologic screening for papillomavirus, 13, 22
 self-administered screening for, 3
 tumor markers in, 45
 conization of, endometrial sampling with, 28
 ripening of, 476
 mechanical methods in, 476
 medical methods in, 476
 Cesarean section
 anesthesia for, in preeclampsia, 421
 incidence in dystocia, 464
 in postdates pregnancy, 150
 vaginal birth after, 445
 Cholesterol levels, postmenopausal estrogen therapy affecting, 894
 Chorionic gonadotropin, as marker for gestational trophoblastic disease, 45
 Chromosome abnormalities, fetal growth in, 99, 119
 and karyotyping with cordocentesis sample, 126
 Circadian rhythms, and premenstrual syndrome, 599, 634
 Clinical trials, ethical issues in, 837
 Clomiphene, as therapy for menopausal symptoms, 884
 Clomipramine, in premenstrual syndrome, 634, 664
 Clonidine
 for menopausal symptoms, 884
 in premenstrual syndrome, 664
 Coagulation system
 normal hemostasis in, 338
 in normal pregnancy, 340
 in preeclampsia, 325, 340
 anesthetic implications of, 415
 regulatory mechanisms in, 339
 Cocaine use in pregnancy, and ethical challenges in medical care, 803
 Computed tomography
 integration with MRI in cancer treatment planning, 55
 in pelvimetry, 570
 Congenital anomalies
 and intrauterine growth retardation, 99
 management in third trimester, 792
 Connexins, in uterine excitation-contraction coupling, 494
 Contraception, in women aged 40 and older, 855
 Contraceptives, oral, in premenstrual syndrome, 634, 655
 Copper role in premenstrual syndrome, 676
 Cordocentesis, in intrauterine growth retardation, 126
 Corticosteroid therapy, and osteoporosis, 901
 Cortisol levels, in premenstrual syndrome, 587, 599
 Cryopreservation of preembryos, ethical issues in, 749
 Crystalloids, for distention of uterus in hysteroscopy, 217
 Cytokines, as markers in gynecologic cancers, 45
 Cytology
 cervical and vaginal
 Bethesda classification system in, 22
 and MY-PAP self-administered device for cancer screening, 3
 interpretation of fine-needle aspirates in, 73
 intrauterine, in endometrial cancer diagnosis, 28
 Dairy product intake, and premenstrual syndrome, 676
 Danazol
 for menopausal symptoms, 884
 in premenstrual syndrome, 634, 655
 Densitometry, in osteoporosis diagnosis, 901, 913
 Depression
 in premenstrual syndrome, 587, 599, 612
 serotonin metabolism in, 626
 Dextran-70, for distention of uterus in hysteroscopy, 217, 227, 272, 273, 283
 complications from, 258
 Dextrose 5%, for distention of uterus in hysteroscopy, 243, 283
 Diabetes mellitus, pregnancy in
 and macrosomic fetus, 138. *See also* Macrosomia
 uteroplacental blood flow in, 108
 Diazepam, in eclamptic seizures, 366, 369
 Diet. *See* Nutrition
 Dilapan, for cervical ripening, 476
 Dilatation and curettage (D&C), diagnostic value of, 28
 Diuretics, in premenstrual syndrome, 634
 DNA, papillomavirus, hybridization techniques, 13, 22
 Doppler flow velocimetry in pregnancy, 155, 357, 387
 in hypertension, 387
 in intrauterine growth retardation, 126, 155
 in preeclampsia prediction, 357
 Down syndrome, fetal growth in, 99, 119
 Doxepin, in premenstrual syndrome, 634
 Drug abuse in pregnancy
 and ethical challenges in medical care, 803
 and fetal growth, 99
 Dystocia, oxytocin in, 464
 Eclampsia, seizure prophylaxis in, 365
 anesthetic implications of, 416
 Edema
 cerebral, in preeclampsia, 514
 in premenstrual syndrome, 634

pulmonary
and fluid management during labor, 505, 514
in preeclampsia, 405

Edwards syndrome, fetal growth in, 119

Electrical injuries from hysteroscopy, 259

Electrocoagulation, in hysteroscopic sterilization, 284

Electrosurgery principles, in operative hysteroscopy, 262

Emergencies, in preeclampsia, 402

Encephalocele, occipital, management in third trimester, 792

Endometritis, from hysteroscopy, 259

Endometrium
cancer of
integration of CT and MRI for treatment planning in, 55
progesterins in, 871
revised FIGO staging systems for, 89
tumor markers in, 45
sampling guidelines, 28

EndoPap sampler, in detection of endometrial pathology, 28

Endorphin levels, in premenstrual syndrome, 599, 612

Endoscopy, and operative hysteroscopy. *See Hysteroscopy, operative*

Endothelin, role in preeclampsia, 328

Endothelium-derived relaxing factor, role in preeclampsia, 324

Epidural analgesia
affecting uterine activity in labor, 457
plasma volume loading with, 514

Equipose, collective, and ethics of clinical trials, 837

Erythroblastosis, in fetal hypoxia, 126

Erythrocyte mean corpuscular volume in intrauterine growth retardation, 126

Estradiol
and brain excitability, 612
and serotonin levels in brain, 626

Estrogens
affecting uterine gap junction formation, 494
in contraceptives for women aged 40 and older, 855
role in premenstrual syndrome, 587, 599, 612
therapy with
alternatives to, for menopausal symptoms, 884
and breast cancer risk, 871, 923
guidelines for, 871
and heart disease, 894
in osteoporosis, 901, 913
in premenstrual syndrome, 634, 655
progesterins with, and endometrial sampling, 28

Ethics, obstetric, 709
in abortion debate, 783
and anencephalic infants as organ donors, 821
in assisted reproduction, 749
and beginning of human life, 720
in clinical trials, 837
issues in HIV infection, 813
and managing fetal anomalies in third trimester, 792
maternal-fetal conflict in, 729
legal dimensions of, 738
in medical care for pregnant substance abuser, 803
in reproductive genetics, 763
review questions, 855
teaching of, in residency programs, 846
in ultrasonography, 758

Etidronate, in osteoporosis, 901, 913

Exercise, in premenstrual syndrome, 634

Factor VIII
in preeclampsia, 343
in pregnancy, 340

Fallopian tubes
catheterization procedures, 301
fluoroscopic-guided, 301
hysteroscopic-guided, 301
ultrasound-guided, 302
hysteroscopic endotuboplasty of, 299

Fallopscopy, hysteroscopic, 303
applications of, 306
outcomes after, 308
technique of, 304

Fat intake, and premenstrual syndrome, 676

Fatigue, in premenstrual syndrome, 634

Fenfluramine, in premenstrual syndrome, 664

Fentanyl
affecting uterine activity in labor, 457
in pregnancy-induced hypertension, anesthetic implications of, 418

Fertilization in vitro, ethical issues in, 749

α -Fetoprotein, in preeclampsia prediction, 358

Fetus
abdominal circumference in, 172
alcohol syndrome affecting growth, 99
assessment of behavior patterns in, 185
and beginning of human life, 720
biophysical profile of, 185
biparietal diameter in, 172
blood flow velocity studies, 155, 185
blood sampling with cordocentesis, 126
growth of, 97. *See also Growth, fetal*
uteroplacental blood flow affecting, 108
heart rate of
amniotomy affecting, 535
oxytocin affecting, 464

Macrosomia of. *See Macrosomia*

management of anomalies in third trimester, 792

maternal-fetal conflict, 729
legal dimensions of, 738
measurements for fetal-pelvic index, 570
as a patient, 709
risks in labor after prior cesarean section, 445
therapy for, ethical issues in, 763
thigh-calf circumference in, 172
tissue transplant research, ethical issues in, 763
transverse cerebellar diameter of, 172
ultrasound evaluation during labor, 527
viability of
issues in, 720
and termination of pregnancy, 729

weight estimation in, 172

Fibrinolytic system, 339
in preeclampsia, 326, 345

Fibronectins, in preeclampsia prediction, 359

Fluid management during labor, 505
and plasma volume status, 514

Fluid retention, in premenstrual syndrome, 634

Fluoride therapy, in osteoporosis, 901, 913

Fluoxetine, in premenstrual syndrome, 634, 664

Forceps deliveries, 487
guidelines for, 487

Foreign bodies in uterus, hysteroscopic removal of, 270

Gametes
extraconjugal, for assisted reproduction, ethical issues in, 749
intrafallopian transfer (GIFT), ethical issues in, 749

Gap junctions (GJs), role in uterine contractility, 494

Genetics
reproductive, ethical issues in, 763
and uterine contractility regulation, 494

Ginseng, as therapy for menopausal symptoms, 884

Glucose levels
and fluid management during labor, 505
in intrauterine growth retardation, 126

Glycine, for distention of uterus in hysteroscopy, 226, 243
complications from, 258

Gonadotropin-releasing hormone agonists, in premenstrual syndrome, 634, 655

Growth, fetal, 97
in aneuploidies, 99, 119
assessment with cordocentesis, 126
discordancy in twins, 155
graphic display of biometric parameters in, 194
macrosomia in. *See* Macrosomia
morphometric ratios in, 172
oligohydramnios affecting, 126, 172, 185
retardation of
 antenpartum and intrapartum management of, 185
 asymmetrical, 194
 classification of, 99
 definition of, 99
 diagnosis with ultrasound, 172
 etiology of, 99
 femur-sparing, 194
 maternal and fetal blood flow velocity studies in, 155, 185
 symmetrical, 194
review questions, 203
short femur in, 194
small head in, 194
uteroplacental blood flow affecting, 108

Halothane, affecting uterine activity in labor, 457

Head size, fetal
 in macrosomia, 172
 small, 194

Headache, in menstrual migraine, 634

Heart disease, postmenopausal estrogen therapy affecting, 894

Heart rate, fetal
 amniotomy affecting, 535
 monitoring in intrauterine growth retardation, 126, 185
 oxytocin affecting, 464

HELLP syndrome in preeclampsia, 346, 409
 anesthetic implications of, 416

Hemorrhage, from operative hysteroscopy, 257

Histrelin, in premenstrual syndrome, 655

HIV infection in pregnancy, ethical issues in, 813

Hormone replacement therapy, and endometrial sampling, 28

Hybridization techniques, in screening for papillomavirus, 13, 22

Hydralazine in pregnancy-induced hypertension, anesthetic implications of, 417

Hydrocephaly, management in third trimester, 792

4-Hydroxyandrostenedione, as therapy for menopausal symptoms, 884

Hygroscopic dilators, for cervical ripening, 476

Hypertension in pregnancy, 317. *See also* Preeclampsia and fetal growth, 99

Hypoglycemia, and intrauterine growth retardation, 126

Hypoxia
 fetal, diagnosis with cordocentesis, 126
 maternal, and fetal growth, 99, 185

Hyskon. *See* Dextran-70

Hysterectomy
 indications for, 865
 oophorectomy with, 923
 and preoperative endometrial sampling, 28

Hysteroscopy, operative, 209
 in abnormal uterine bleeding, office procedure in, 270
 in adhesiolysis, 235
 lasers in, 247
 as office procedure, 271
 resectoscope in, 254
 auxiliary instruments in, 213
 complications of, 256
 electrical and laser injuries in, 259
 hemorrhagic, 257
 infection, 259
 traumatic, 256
 contact scopes in, 225
 distention of uterus in, 215, 225, 283
 carbon dioxide in, 216, 227, 272, 273, 283
 complications from, 258, 284
 crystalloids in, 217
 dextran-70 in, 217, 227, 272, 273, 283
 dextrose 5% in, 243, 283
 in laser surgery, 243
 saline or Ringer's lactate in, 243
 sorbitol or glycine in, 226, 243
 water or saline in, 225
 endometrial ablation in
 complications of, 260
 lasers in, 245
 resectoscope in, 252
 and endometrial sampling, 28
 endotuboplasty techniques in, 299
 in falloposcopy, 303
 in transcervical balloon tuboplasty, 303
 in tubal catheterization, 301
 failure and poor outcome of, 260
 in foreign body removal, office procedure in, 270
 hysteroscope systems in, 211
 in infertility, 229
 office procedure in, 271
 instrumentation in, 211, 282
 in laser surgery, 243
 in office procedures, 271
 lasers in, 214, 242, 265
 adhesiolysis in, 247
 distending media for, 243
 endometrial ablation in, 245
 equipment for, 243
 injury from, 259

necrosis of tissue in, 244
 removal of large polyps and submucous fibroids
 in, 246
 septal incision in, 246
 sterilization technique in, 247
 types of, 242
 vaporization of tissue in, 244
 in myoma resection, 218
 lasers in, 246
 in office setting, 270, 276
 resectoscope in, 251
 in office setting, 270
 for adhesiolysis, 276
 contraindications to, 271
 distention media in, 272, 273
 indications for, 270
 instrumentation for, 271
 for lost intrauterine device, 275
 for myoma resection, 270, 276
 for polyps removal, 278
 procedure in, 273
 reimbursement for, 280
 for retained products of conception, 279
 for septic uterus, 276
 in polyps removal
 lasers in, 246
 in office setting, 278
 pre-operative medication in
 in laser surgery, 245
 in resectoscopic surgery, 254
 resectoscopes in, 214, 250
 and principles of electrosurgery, 262
 review questions, 313
 septal incision in, 229, 246
 lasers in, 246
 as office procedure, 271, 276
 resectoscope in, 254
 for sterilization, 282. *See also* Sterilization, hysteroscopic
 submucous myoma resection in, 237

Infections
 congenital
 diagnosis with cordocentesis, 126
 and intrauterine growth retardation, 99
 from hysteroscopy, 259

Infertility
 and ethical issues in assisted reproduction, 749
 operative hysteroscopy in, 229
 endotuboplasty in, 299
 in office setting, 271

Inositol 1,4,5-triphosphate, affecting uterine contractility, 494

Insulin levels, in intrauterine growth retardation, 126

Interleukin-6, as marker in gynecologic cancer, 45

Intrauterine contraceptive device, lost, operative hysteroscopy for, 275

In vitro fertilization, ethical issues in, 749

Ketamine, affecting uterine activity in labor, 457

Ketosis, and fluid management during labor, 505

Kidneys in preeclampsia, 323
 acute failure in, 408

Koilocytosis, in Bethesda system for cytologic diagnosis, 22

Labetalol in pregnancy-induced hypertension, anesthetic implications of, 418, 419

Labor
 after prior cesarean section, 445
 amniotomy in, 535
 analgesia in
 effects of, 457
 in preeclampsia, 420
 bleeding in, ultrasound evaluation of, 527
 cervical ripening in, 476
 fetal-pelvic relationships in, 570
 fluid management in, 505
 and plasma volume status, 514
 operative vaginal delivery in, 487
 oxytocin in, 464
 posture and position in, 535
 preterm
 saline loading in, 505
 ultrasonography in, 527
 review questions, 583
 ultrasonography in, 527
 uterine contractility in, 457
 assessment of, 546
 molecular biology of, 494
 vaginal breech delivery in, 559

Lamicel, for cervical ripening, 476

Laminaria tents, for cervical ripening, 476

Laser surgery, hysteroscopic, 214, 242, 265
 injury from, 259

Legal aspects
 of abortion debate, 783
 of maternal-fetal conflict, 738

Lidocaine, affecting uterine activity in labor, 457

Life, beginning of, 720

Lipid peroxidation, in preeclampsia, 327

Lithium therapy, in premenstrual syndrome, 664

Liver
 dysfunction of, anesthetic implications of, 416
 in fetal hypoxia, 126
 fine-needle aspiration biopsy of, 73
 subcapsular hematoma rupture in preeclampsia, 409

Lofexidine, as therapy for menopausal symptoms, 884

Lungs, fine-needle aspiration biopsy of, 73

Luteal phase dysphoric disorder, 587, 599

Lymph nodes, fine-needle aspiration biopsy of, 73

Macrophage colony-stimulating factor, as marker in gynecologic cancer, 45

Macrosomia
 chest and abdomen in, 1724
 diagnosis with ultrasound, 172
 head size in, 172
 in infants of diabetic mothers, 138
 and labor after prior cesarean section, 445
 in postdates pregnancy, 150
 review questions, 203

Magnesium deficiency, and premenstrual syndrome, 634, 676

Magnesium sulfate in eclamptic seizures, 366
 anesthetic implications of, 416

Magnetic resonance imaging
 integration with CT in cancer treatment planning, 55
 in pelvimetry, 570

Marijuana use in pregnancy, and ethical challenges in medical care, 803

Mastalgia, in premenstrual syndrome, 634

Medroxyprogesterone acetate
for menopausal hormone replacement, 871
in premenstrual syndrome, 634, 655
as therapy for menopausal symptoms, 884

Mefenamic acid, in premenstrual syndrome, 634

Melatonin levels, in premenstrual syndrome, 587, 599

Membrane stripping, for cervical ripening, 476

Menopause
alternatives to estrogen therapy in, 884
and contraception for women aged 40 and older, 855
decisions for hysterectomy in, 865
estrogen and progestin therapy in, 871
normal view of, 923
osteoporosis in, 901
hormonal management of, 913
review questions, 935

Menstrual cycle
abnormal bleeding in, and endometrial sampling guidelines, 28
cognitive processing in, 690
dysphoria in. *See* Premenstrual syndrome

Meperidine, affecting uterine activity in labor, 457

Methyldopa, as therapy for menopausal symptoms, 884

Migraine, menstrual, 634

Mineral supplements, in premenstrual syndrome, 634, 676

Molecular biology of uterine contractility, 494

Montevideo unit of uterine contractility, 546

Mood disorders, female-specific, 599

Morphine, affecting uterine activity in labor, 457

MY-PAP self-administered device for cervical cancer screening, 3

Myomas of uterus, hysteroscopic surgery in, 237
lasers in, 246
in office setting, 270, 276
resectoscope in, 251

Naloxone, as therapy for menopausal symptoms, 884

Naltrexone, in premenstrual syndrome, 664

Naproxen, in menstrual migraine, 634

Narcotic abuse in pregnancy
and ethical challenges in medical care, 803
and fetal growth, 99

Neuroendocrine factors in premenstrual syndrome, 587, 599, 612
and role of serotonin, 626

Nitroglycerin in pregnancy-induced hypertension, anesthetic implications of, 418

Nitroprusside in pregnancy-induced hypertension, anesthetic implications of, 418

Nitrous oxide, affecting uterine activity in labor, 457

Nortriptyline, in premenstrual syndrome, 664

Nutrition
fetal supplementation in intrauterine growth retardation, 126
maternal, and fetal growth, 99, 185
and osteoporosis prevention, 901
in premenstrual syndrome, 634, 676

Obstetric ethics, 709

Office procedures, operative hysteroscopy in, 270

Oligohydramnios, and intrauterine growth retardation, 126, 172, 185

Oophorectomy
estrogen deficiency from, 923
in premenstrual syndrome, 634

Opiates
abuse in pregnancy
and ethical challenges in medical care, 803
and fetal growth, 99
endogenous, in premenstrual syndrome, 599, 612

Osmolality of plasma, and fluid management during labor, 505

Osteoporosis, 901
hormonal management of, 913

Ovariectomy, estrogen deficiency from, 923

Ovaries, cancer of
integration of CT and MRI for treatment planning in, 55
transvaginal ultrasound screening for, 40
tumor markers in, 45

Oxygen free radicals, in preeclampsia, 327

Oxygen therapy, maternal, in intrauterine growth retardation, 126, 185

Oxygenation, maternal, and fetal growth, 99

Oxytocin, 464
challenge test as indicator of fetal hypoxia, 185
dextrose in water with, hyponatremia from, 505
in labor after prior cesarean section, 445
receptors for, regulatory control of, 494

Papanicolaou smears
as aid in endometrial cancer diagnosis, 28
and MY-PAP self-administered device for cervical cancer screening, 3

Papillomavirus, molecular biologic screening for, 13, 22

Parathyroid hormone therapy, in osteoporosis, 913

Patau syndrome, fetal growth in, 99, 119

Pelvimetry, and fetal-pelvic relationships, 570

Pelvis, fine-needle aspiration biopsy of, 73

Personality factors, in premenstrual syndrome, 587

Phenytoin, in eclamptic seizures, 366

Pipelle device, for endometrial sampling, 28

Placenta
abnormalities of, and intrauterine growth retardation, 99
previa, ultrasonography of, 527
sonographic changes in, 172

Platelets
in preeclampsia, 325, 344, 343
calcium metabolism in, 360
in pregnancy, 340
role in hemostasis, 339

Polycarbophil, as vaginal lubricant, 884

Polyps of uterus, hysteroscopic removal of, 278
lasers in, 246

Postdates pregnancy, macrosomia in, 150

Posture and position in labor, 535

Preeclampsia, 315
anesthesia for cesarean delivery in, 421
antihypertensive agents in, affecting anesthesia, 417
antithrombin III therapy in, 347
antithrombin levels in, 343
aspirin in prevention of, 352
blood volume in, affecting anesthesia, 416

cardiopulmonary arrest in, 410
 cerebral blood flow in, affecting anesthesia, 416
 coagulation system in, 325, 340
 anesthetic implications of, 415
 counseling in, 433
 definition of, 352
 and Doppler flow velocimetry in hypertensive pregnancy, 387
 endothelial dysfunction in, 322
 epidural analgesia for labor in, 420
 factor VIII antigen/activity ratio in, 343
 fibrin formation in, 342
 fibrinolytic system in, 326, 345
 fluid management in, 514
 genetic factors in, 318, 353
 HELLP syndrome in, 346, 409
 anesthetic implications of, 416
 hemodynamic changes in, 375
 anesthetic implications of, 414
 hepatic subcapsular hematoma rupture in, 409
 hepatocellular dysfunction in, anesthetic implications of, 416
 hypertensive emergencies in, 402
 immunologic factors in, 318, 319
 intracranial pressure increase in, 404
 mild, management of, 427
 neonatal effects of, 346
 neutrophil activation in, 319
 and normal physiology of vascular endothelium, 320
 oxygen free radicals in, 327
 pathogenesis of, 317
 plasma exchange in, 347
 platelets in, 325, 343
 portable blood pressure monitoring in, 395
 prediction of, 346, 351
 alpha-fetoprotein in, 358
 blood pressure in early pregnancy, 354
 Doppler velocimetry in, 357
 fibronectins in, 359
 parity and family history in, 353
 platelet calcium metabolism in, 360
 pressor tests in, 355
 uric acid levels in, 357
 urinary albumin and calcium in, 360
 pulmonary edema in, 405
 renal function in, 323
 acute failure in, 408
 anesthetic implications of, 416
 review questions, 437
 seizure prophylaxis in, 365
 affecting anesthesia, 416
 severe, management of, 429
 in second trimester, 430
 treatment of, 347, 427
Pregnancy
 in assisted reproduction, ethical issues in, 749
 and beginning of human life, 720
 blood flow velocity studies in, 108, 155, 357, 387
 coagulation in, 340
 in diabetes mellitus
 macrosomic fetus in, 138. *See also Macrosomia*
 uteroplacental blood flow in, 108
 fetal growth in, 97. *See also Growth, fetal*
 HIV infection in, 813
 hypertension in, 317. *See also Preeclampsia*
 maternal-fetal conflict in, 729
 legal dimensions of, 738
 postdates, macrosomia in, 150
 substance abuse in, and ethical challenges in medical care, 803
 uterine contractility in, 546
Premenstrual syndrome
 biochemical markers in, 587
 circadian rhythms affecting, 599, 634
 cognitive model of, 690
 diagnostic issues in, 587, 634
 differential diagnosis of, 587
 and female-specific mood disorders, 599
 management of, 634
 hormonal manipulation in, 655
 psychotropic drugs in, 664
 neuroendocrine factors in, 587, 599, 612
 nutritional factors in, 634, 676
 research issues in, 587
 review questions, 699
 serotonin role in, 626
 stress factors in, 587
 reduction of, 634, 690
 symptoms of, 587, 612, 634
Prenatal diagnosis
 ethical issues in, 763
 and management of fetal anomalies in third trimester, 792
Preterm labor
 saline loading in, 505
 ultrasonography in, 527
Progesterone
 affecting uterine gap junction formation, 494
 and brain excitability, 612
 metabolism in brain, 612
 role in premenstrual syndrome, 587, 599, 612
 and serotonin levels in brain, 626
 as therapy in premenstrual syndrome, 634, 655
Progestins
 in contraceptives for women aged 40 and older, 855
 for menopausal hormone replacement, 871
 for menopausal symptoms, 884
 in osteoporosis, 913
Prolactin levels in premenstrual syndrome, 599
Prostacyclin, role in preeclampsia, 323
Prostaglandins
 for cervical ripening, 476
 interaction with uterine gap junctions, 494
 serum levels in premenstrual syndrome, 599, 612
Psychologic aspects
 of female-specific mood disorders, 599
 of premenstrual syndrome, 587
 and stress reduction, 634, 690
Psychotropic drugs, in premenstrual syndrome, 664
Pulmonary edema
 and fluid management during labor, 505, 514
 in preeclampsia, 405
Radiation therapy, portal design with CT and MRI in, 55
Radiography, pelvimetry in, 570
Relaxation therapy, in premenstrual syndrome, 634, 690
Relaxin, for cervical ripening, 476
Renal arteries, in preeclampsia, 390

944 INDEX

Resectoscope in hysteroscopic surgery, 214, 250
and principles of electrosurgery, 262
Roll-over test, in preeclampsia prediction, 356
RU-486, as contraceptive, 855

Saline infusions, and fluid management during labor, 505, 514
Salpingoscopy, 300
Salt intake, and premenstrual syndrome, 676
Scintigraphy, in uteroplacental blood flow measurements, 108

Seizures
eclamptic, prophylaxis of, 365
anesthetic implications of, 416
and hormonal variations in menstrual cycle, 612

Serotonin role in premenstrual syndrome, 626

Shoulder dystocia, in postdates pregnancy, 150

Sleep disorders, in premenstrual syndrome, 634

Smoking in pregnancy
and ethical challenges in medical care, 803
and fetal growth, 99

Sodium levels, and fluid management during labor, 505

Sorbitol, for distention of uterus in hysteroscopy, 226, 243
complications from, 258

Spleen, fine-needle aspiration biopsy of, 73

Squamous cell carcinoma antigen (SCC), as marker in gynecologic cancers, 45

Sterilization, hysteroscopic, 282
electrocoagulation in, 284
lasers in, 247
problems in, 293
reversibility of, 296
tubal plugs in, 285
ceramic, 286
formed-in-place silicone, 288
hydrogelic, 286
nylon, 288
polyethylene, 287
preformed silicone, 287

Steroids, anabolic, in osteoporosis, 901

Stress, and premenstrual syndrome, 587
relaxation techniques in, 634, 690

Suction devices for endometrial sampling, 28

Sugar intake, and premenstrual syndrome, 676

Surgery
and estrogen deficiency from oophorectomy, 923
hysteroscopy in. *See Hysteroscopy, operative indications for hysterectomy, 865*

Surrogate pregnancy, ethical issues in, 749

Synechiae. *See Adhesiolysis, hysteroscopic*

Tamoxifen
in atrophic vaginitis, 884
and endometrial cancer, 28

Teaching of biomedical ethics, in residency programs, 846

Thiazide therapy, in osteoporosis, 901

Thrombocytopenia, in preeclampsia, 343

Thromboxane, role in preeclampsia, 323

Thyroid hormone therapy, and osteoporosis, 901

Thyroid-stimulating hormone, response to TRH in premenstrual syndrome, 587, 599

Tis-U-Trap, for endometrial sampling, 28

Tobacco use in pregnancy
and ethical challenges in medical care, 803
and fetal growth, 99

Tocography, 546

Transplantation of organs, from anencephalic donors, 821

Trials, clinical, ethical issues in, 837

Tricyclic antidepressants, in premenstrual syndrome, 634, 664

Triglyceride levels, in intrauterine growth retardation, 126

Trimethaphan in pregnancy-induced hypertension, anesthetic implications of, 418, 419

Trisomy 13, fetal growth in, 99, 119

Trisomy 18, fetal growth in, 99, 119

Trisomy 21, fetal growth in, 99, 119

Trophoblastic disease, gestational, tumor marker in, 45

Tubal surgery, hysteroscopic endotuboplasty in, 299

Tumors
Bethesda system for cervical/vaginal cytologic diagnoses in, 22
breast cancer risk in estrogen therapy, 871, 923
endometrial sampling guidelines in, 28
fine-needle aspiration biopsy in, 73
integration of CT and MRI for treatment planning in, 55
markers in, 45
and molecular biologic screening for papillomavirus, 13, 22
new diagnostic techniques in, 1
review questions, 95
progestins in endometrial cancer, 871
revised FIGO staging systems in, 89
self-administered screening for cervical cancer, 3
transvaginal ultrasound screening for ovarian cancer, 40

Turner syndrome, fetal growth in, 99, 119

Twin pregnancies
growth discordancy in, 155
intrauterine growth retardation in, 99
selective abortion in, ethical issues in, 763
ultrasound evaluation of, 527

Ultrasonography
in diagnosis of intrauterine growth retardation, 172
Doppler flow velocimetry in pregnancy, 155, 357, 387
in hypertension, 387
in intrauterine growth retardation, 126, 155
in preeclampsia prediction, 357

in estimation of fetal weight, 172

ethical issues in obstetrics, 758

in fetal and pelvic measurements, 570

in labor, 527

in macrosomia diagnosis, 172
in infants of diabetic mothers, 138

transvaginal
color imaging of blood flow in early pregnancy, 185
and endometrial sampling, 28
in screening for ovarian cancer, 40
in tubal catheterization, 302

Umbilical circulation
in hypertension, 390
in intrauterine growth retardation, 155

Umbilical cord, cordocentesis in intrauterine growth retardation, 126

Uric acid levels, in preeclampsia prediction, 357

Urinary gonadotropin fragment (UGF), as marker in gynecologic cancers, 45

Urine production, fetal, in intrauterine growth retardation, 126, 185

Uterine arteries
abnormal, 392
in hypertension, 388

Uteroplacental circulation, 108
abnormal, 391

Doppler flow velocimetry of
in hypertensive pregnancy, 387
in preeclampsia prediction, 357
in intrauterine growth retardation, 126, 155
normal, 391

Uterus. *See also Cervix uteri; Endometrium*
blood flow affected by plasma volume expansion, 514

contractility of
abnormal patterns in, 546
analgesic agents affecting, 457
assessment of, 546
calcium affecting, 494
in labor, 457, 546
molecular biology of, 494
in pregnancy, 546

gap junction proteins in, 494

operative hysteroscopy of. *See Hysteroscopy, operative*

scar dehiscence and rupture, 445
pregnancy after, 445
sensitivity to oxytocin, 464

Vabra aspiration, in detection of endometrial pathology, 28

Vacuum extractors, 487
guidelines for use of, 487

Vagina
atrophy in menopause, management of, 884
cancer of, integration of CT and MRI for treatment planning in, 55

Vascular endothelium
dysfunction in preeclampsia, 322
normal physiology of, 320
role in hemostasis, 339

Vasomotor symptoms in menopause, management of, 884

Video equipment, in operative hysteroscopy, 218

Vitamin D, and osteoporosis prevention, 901, 913

Vitamin therapy, in premenstrual syndrome, 634, 676

Vulva, cancer of
integration of CT and MRI for treatment planning in, 55
revised FIGO staging systems for, 89
tumor markers in, 45

Water in body, and fluid management during labor, 505

Weight, fetal
estimation with ultrasound, 527
gain in. *See Growth, fetal*

Yogurt, added to douche water, 884

Zinc role in premenstrual syndrome, 676

Author

Index

Andersen, H. Frank, 527
Anderson, Mark, 55
Backström, Torbjörn, 612
Barton, John R., 402
Bast, Robert C., Jr., 45
Beller, Fritz K., 720, 821
Berchuck, Andrew, 45
Berg, Teresa G., 457
Boente, Matthew P., 45
Brooks, Philip G., 209, 249, 256
Callahan, Daniel, 783
Campbell, Deborah E., 803
Carlson, Jay W., 13
Chambers, Joseph T., 28
Chambers, Setsuko K., 28
Chervenak, Frank A., 709, 758
Chervenak, Judith L., 151
Chuong, C. James, 679
Clark, Steven L., 194
Clarke-Pearson, Daniel L., 73
Cooper, Jay M., 282
Corbin, Alan, 855
Corson, Stephen L., 229
Dawson, Earl B., 679
Dekker, Gustaaf A., 317
DePriest, P. D., 40
Divon, Michael Y., 97, 099, 156, 172
Droste, Sabine, 119
Easterling, Thomas R., 375
Elkins, Thomas E., 846
Evans, Mark I.
Farmakides, G., 387
Fleischman, Alan R., 803
Fletcher, John C., 763
Fraser, William D., 535
Friedman, Steven A., 365
Garfield, Robert E., 494
Gimpelson, Richard J., 270
Given, Fred T., Jr., 3
Glezerman, Marek, 126
Haas, Susan T., 865
Hales, Kurt A., 570
Hankins, Gary D. V., 487
Harbert, Guy M., Jr., 546
Hauth, John C., 464
Hayashi, Robert H., 443
Herbst, Arthur L., 22
Holzgreve, Wolfgang, 821
Homesley, Howard D., 89
Hsu, Helen W., 156
Indman, Paul D., 211
Johnson, Susan R., 637
Jones, Howard W., III, 3
Jones, Howard W., Jr., 749
Jones, Kirtly Parker, 854, 871
Kaltenborn, K. C., 901
Kaplan, Peter W., 365
Kerin, John F., 299
Kinney, Walter, 55
Kohler, Matthew F., 73
Kurjak, Asim, 185
Lilford, Richard J., 837
Lofter, Franklin D., 242
Lunell, Nils-Olov, 108
Mahowald, Mary B., 729
Martin, James N., Jr., 338
McCullough, Laurence B., 709, 758
Meizner, Israel, 126
Miller, Karen, 884
Minkoff, Howard, 813
Moreno, Jonathan D., 813
Morgan, Mark A., 570
Mortola, Joseph F., 587
Muse, Kenneth, 658
Neiger, Ran, 138
Nelson, Lawrence J., 738
Nylund, Lars, 108
O'Brien, William F., 351
Owen, John, 464
Perry, Kenneth G., Jr., 338
Plouffe, Leo, 667
Podratz, Karl C., 1
Pollack, Raphael N., 99
Pridjian, Gabriella, 445
Ramanathan, Jaya, 414
Rapkin, Andrea J., 585, 629
Rausch, Jeffrey L., 667
Ravnikar, Veronica A., 913
Rayburn, William F., 395, 457
Reading, Anthony E., 693
Repke, John T., 365
Russell, Anthony H., 55
Schneider, E., 387
Schulman, H., 387

Scudder, Sidney, 55
Sibai, Baha M., 315, 402, 426
Smith, Lloyd, 55
Soderstrom, Richard M., 225, 262
Sokol, R., 535
Steiner, Meir, 599
Strong, Carson, 792
Surrey, Eric S., 299
Tabb, Thomas N., 494
Thurnau, Gary R., 570
Trofatter, Kenneth F., Jr., 476
Twiggs, Leo B., 13
Upton, G. Virginia, 855
van Nagell, J. R., Jr., 40
Voda, Ann M., 923
Walsh, Brian W., 894
Walter, John, 55
Wasserstrum, Nathan, 505, 514
Weiner, Carl P., 559
Weston, Susan, 667
Yeomans, Edward R., 487
Zeeman, Gerda G., 317
Zimmer, Etan Z., 172
Zlatnik, Gail P., 720
Zmijanac, Jasenka, 185
Zuspan, Frederick P., 395